Introduction {#Sec1}
============

Ceftolozane/tazobactam is an antibacterial agent that shows potent in vitro activity against many extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and drug-resistant *Pseudomonas aeruginosa*, including multidrug-resistant and extremely drug-resistant isolates \[[@CR1]--[@CR3]\]. Ceftolozane/tazobactam is approved for the treatment of complicated intraabdominal infections (cIAI) when used in combination with metronidazole and for complicated urinary tract infections (cUTI), including pyelonephritis \[[@CR4]\].

In pharmacokinetic (PK) studies, ceftolozane/tazobactam demonstrated dose-dependent, linear PK with no clinically relevant drug accumulation with standard every-8-h dosing \[[@CR4], [@CR5]\]. Because ceftolozane/tazobactam is eliminated primarily by the kidneys, dosages must be adjusted to account for impaired renal function, specifically for patients with creatinine clearance (CrCl) ≤50 mL/min \[[@CR4], [@CR6]\]. The primary objective of this analysis was to simulate the probability of PK/pharmacodynamic (PD) target attainment of ceftolozane/tazobactam in patients with varying degrees of renal impairment, including augmented renal clearance (ARC) and end-stage renal disease (ESRD).

Methods {#Sec2}
=======

Population PK Model for Simulation {#Sec3}
----------------------------------

In the current analysis, PK/PD target attainment for ARC, normal renal function, and mild, moderate, or severe renal impairment was simulated based on a previously developed population PK model in which CrCl was a significant covariate \[[@CR7]\]. The model was developed with the data from ten clinical studies (eight phase 1 and two phase 2 studies) in healthy subjects with normal renal function, subjects with mildly impaired, moderately impaired, or severely impaired renal function, and patients with cUTI or cIAI \[[@CR7]\]. These data included the plasma concentrations of ceftolozane and tazobactam that were collected following intravenous administration of ceftolozane/tazobactam, ceftolozane alone, or tazobactam alone. A two-compartment disposition model with zero-order input and first-order elimination best characterized the plasma concentration--time data for both ceftolozane and tazobactam \[[@CR7]\].

PK/PD target attainment for ESRD was simulated based on a previously described population PK model \[[@CR8]\]. This model was developed from a PK study in six subjects with ESRD undergoing high-flux hemodialysis (HD) with either Revaclear (Gambro, Stockholm, Sweden) or CT 190G (Baxter Healthcare, McGaw Park, IL, USA) hemodialyzers, and a target adequacy (Kt/V) of at least 1.2 for a minimum of 3 months before enrollment \[[@CR6]\]. Subjects were administered a single dose of ceftolozane/tazobactam without HD (i.e., ceftolozane/tazobactam immediately after HD), followed by a washout period with PK sampling, and then a second dose administered 2 h before a 4-h HD, with intensive PK sampling before and after HD. The collected PK data was then fitted with a nonlinear mixed-effects model with Phoenix NLME software, v.1.2 (Certara L.P. Pharsight, St. Louis, MO, USA). This population PK model is also a two-compartment disposition model to describe the ceftolozane or tazobactam plasma concentration--time data without HD and HD was included as a covariate effect on both clearance and volume of distribution for the central compartment \[[@CR8]\].

Monte Carlo Simulation {#Sec4}
----------------------

Monte Carlo simulations using the population PK models were performed for 1000 patients in each renal function category; 5000 patients were simulated for ESRD. The renal function categories included ARC (CrCl, \>150 to ≤200 mL/min), normal renal function (CrCl, \>90 to ≤150 mL/min), mild renal impairment (CrCl, \>50 to ≤90 mL/min), moderate renal impairment (CrCl, ≥29 to ≤50 mL/min), severe renal impairment (CrCl, ≥15 to \<29 mL/min), and ESRD (CrCl, \<15 mL/min). These categories of renal impairment were defined before the US Food and Drug Administration (FDA) updated guidance in 2010 \[[@CR9]\], which redefined the cutoff for moderate renal impairment to 30--59 mL/min, and were retained for consistency of category definitions across trials in the ceftolozane/tazobactam clinical development program. A separate analysis (included in the New Drug Application submission but not shown here) confirmed that definition of renal impairment categories based on the updated guidance would not change the conclusions. In each simulation, except for ESRD, body weight was sampled from a log-normal distribution in the form of 74 × exp\[*N*(0, 0.205^2^)\] kg, where *N*(0, 0.205^2^) stands for a normal distribution at a mean of 0 with a standard error of 0.205. This was representative of patients included in the phase 1 and phase 2 clinical trials. In simulations for ESRD, body weight was not relevant because it was not included in the PK model.

Simulated intravenous dosing regimens, administered over 1 h every 8 h, were based on renal function category and FDA-approved doses \[[@CR4]\]: 1.5 g (1000/500 mg) ceftolozane/tazobactam in patients with ARC, normal renal function, or mild renal impairment; 750 mg (500/250 mg) ceftolozane/tazobactam in patients with moderate renal impairment; 375 mg (250/125 mg) ceftolozane/tazobactam in patients with severe renal impairment; and 750 mg (500/250 mg) ceftolozane/tazobactam loading dose followed by maintenance dose of 150 mg (100/50 mg) ceftolozane/tazobactam over 1 h every 8 h for ESRD. Multiple dialysis scenarios were tested for ESRD; we report here the representative weekly scheme of a 4-h HD on Monday, Wednesday, and Friday (i.e., HD → 2 days → HD → 2 days → HD → 3 days). A dose was administered immediately following each HD, and the single loading dose was used for the first dose only. Up to 2 cycles (14 days) were simulated for each case, and daily target attainment on day 3 (after the second HD) was the lowest and was reported as a conservative approach.

A finite element method with a time step of 0.001 h was used to simulate the total concentration--time profiles based on the following mass balance differential equations for the population PK model:$$\documentclass[12pt]{minimal}
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                \begin{document}$$ {\text{d}}X_{2} /{\text{d}}t \, = {\text{Q}}_{2} /V_{\text{c}} {\cdot}X_{\text{c}} - {\text{ Q}}_{ 2} /V_{ 2} {\cdot}X_{ 2} $$\end{document}$$where *X* ~c~ and *X* ~2~ represent the amount of the drug at time *t* in the central compartment and peripheral compartment, respectively; *R* ~t~ represents the infusion rate at time *t*; Cl and Q~2~ represent the terminal clearance and intercompartmental clearance between the central and peripheral compartments, respectively; and *V* ~c~ and *V* ~2~ represent the volume of distribution for the central and peripheral compartments, respectively. The population PK model parameter estimates were from the previously published population PK models \[[@CR7], [@CR8], [@CR10]\]. To explore the situations in which exposures may be lower in some patients than in typical patients or healthy volunteers at the same dose, however, patients with cIAI were assumed for the simulations. This patient group was selected because it was observed that PK exposure in cIAI patients was lower than in non-cIAI subjects (i.e., cUTI patients or healthy volunteers) \[[@CR7]\]. In addition, interindividual variability for the parameter estimates in the PK models was conservatively inflated to have a 50% coefficient of variation in the log-scale to cover potentially larger variability in real patients.

PK/PD target attainment by minimum inhibitory concentration (MIC) was assessed for ceftolozane by nonclinical PK/PD targets for simulated patients in each renal function category. As with other cephalosporins, the percentage of time with free drug concentration above the MIC (%*f*T \> MIC) was the PD driver for ceftolozane \[[@CR11]\]. The targets for ceftolozane were 24.8% (bacteriostatic), 32.2% (for 1-log kill; bactericidal), and 40% (2-log kill), representing the median  %*f*T \> MIC associated with these levels of activity against Enterobacteriaceae and *P. aeruginosa* in the neutropenic mouse model \[[@CR10]--[@CR13]\]. The percentage of simulated patients who attained these targets during the dosing interval at steady state for MIC values ranging from 0.03 to ≥32 mg/L was determined for each dosing regimen evaluated within each renal function category. The current Clinical and Laboratory Standards Institute (CLSI) \[[@CR14]\] susceptibility breakpoints, which are consistent with the FDA breakpoints, for ceftolozane/tazobactam are 2 mg/L for Enterobacteriaceae and 4 mg/L for *P. aeruginosa*.

The target with tazobactam was to achieve 20% of time above minimum effective concentration (MEC; 20% *f*T \> MEC) of 1 mg/L to effectively inhibit β-lactamases. The rationale for using the 1 mg/L tazobactam threshold is based on several in vitro and in vivo studies. In vitro enzyme-binding studies demonstrated that the concentration of β-lactamase inhibitor required to reduce β-lactamase enzyme activity by 50% (IC~50~) is less than 0.3 mg/L for \>97% of the β-lactamases tested (*n* = 35) and for all class A β-lactamase-producing strains (*n* = 12) \[[@CR15]--[@CR17]\]. Consistent with the IC~50~ values from these in vitro enzyme-binding experiments, the tazobactam threshold value was determined to be ≤1 mg/L across in vitro dose fractionation and in vivo neutropenic mouse thigh infection PD experiments \[[@CR11], [@CR18]\]. Additionally, \<1 mg/L was found to be fully effective against all ten clinical strains tested \[*Escherichia* *coli* (*n* = 6) and *Klebsiella pneumoniae* (*n* = 4)\] in a mouse thigh neutropenic model in which a geometrically averaged 20% *f*T \> threshold of 1 mg/L tazobactam was observed to be efficacious (data on file). Based on exposure--response relationships determined in the neutropenic murine thigh model for ceftolozane combined with tazobactam, the efficacy target for tazobactam for the *f*T \> threshold concentration of 1 mg/L was estimated to be a geometric mean of 19.5% (mean 25.2%; median 21%; range 6.6--51.9%) (internal data). As conceptually illustrated in Fig. [1](#Fig1){ref-type="fig"}, based on the typical tazobactam concentration--time profile following administration of 90 mg tazobactam in cIAI patients with normal renal function, the target of 20% *f*T \> MEC of 1 mg/L is equivalent to the target of 80% *f*T \> threshold of 0.05 mg/mL, which is slightly higher than the target of 70% *f*T \> threshold of 0.05 mg/L for 2-log kill against isolates with low and moderate β-lactamase genetic constructs \[[@CR18]\], and equivalent to the target of 50% *f*T \> threshold of 0.25 mg/L for 1-log kill against isolates with high β-lactamase genetic constructs \[[@CR18]\]. In other words, the target of 20% *f*T \> MEC of 1 mg/L, although derived from the neutropenic mouse thigh infection model, is consistent with and even more strict numerically than other observed in vitro and in vivo targets, such that a dose achieving this target will also achieve the other published targets at least for 1-log kill against even the toughest tested β-lactamase-producing isolates. This is especially true in patients with renal impairment in whom MIC-time profiles display longer half-lives, making it more difficult to achieve a target at a higher concentration threshold than an equivalent target at a lower MIC threshold.Fig. 1Typical tazobactam concentration--time profile (after a 1-h infusion of 90 mg tazobactam in patients with cIAI and normal renal function), showing consistency across different target/threshold settings: 20% *f*T \> MEC of 1 mg/L is equivalent to 50% *f*T \> threshold of 0.25 mg/L and 80% *f*T \> threshold of 0.05 mg/L. The targets are achieved in 50% of patients at a dose of 90 mg and can be achieved in ≥97% patients at the approved dose of 500 mg (covering variability). *cIAI* intraabdominal infection, *fT*  \> *MEC* free-drug time above MEC, *MEC* minimum effective concentration

Against non-ESBL-producing pathogens such as *P. aeruginosa*, only target attainment of ceftolozane is relevant and is thus used for dose selection; however, against ESBL-producing pathogens such as Enterobacteriaceae, it is essential to achieve high target attainment for both ceftolozane and tazobactam simultaneously.

In calculations of %*f*T \> MIC for ceftolozane and %*f*T \> MEC for tazobactam, unbound fractions (*f* ~u~) of 0.79 and 0.70 were used \[[@CR10]\] for the simulated total concentration--time profiles for ceftolozane and tazobactam, respectively.

Statistical analyses and simulations were performed using SAS 9.2 or 9.3 (SAS Institute Inc, NC, USA).

Compliance with Ethics Guidelines {#Sec5}
---------------------------------
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-----------------

The data sets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Results {#Sec7}
=======

PK/PD Target Attainment for Ceftolozane {#Sec8}
---------------------------------------

Systemic exposure to ceftolozane and tazobactam at the approved doses, as reflected by maximum plasma drug concentration (*C* ~max~) and area under the concentration--time curve extrapolated to infinity (AUC~0--∞~), are presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, respectively. Only observed *C* ~max~ and AUC values are reported in the tables; no simulated values. Because no PK data were available from patients with ARC in the clinical trials, no observed values for *C* ~max~ or AUC are available for those patients.Table 1Summary of the observed *C* ~max~ and AUC~0--∞~ after a single dose and simulated probability of ceftolozane target attainment at steady state based on renal functionRenal function category (CrCl, mL/min)TOL/TAZ, mg (1-h infusion)*C* ~max~, µg/mL\
median (range)AUC~0--∞~, µg h/mL\
median (range)PTA  %*f*T \> MIC\
MIC 2 mg/LPTA  %*f*T \> MIC\
MIC 4 mg/LPTA  %*f*T \> MIC\
MIC 8 mg/L24.8%32.2%40.0%24.8%32.2%40.0%24.8%32.2%40.0%ARC (\>150 to ≤200)1000/500NANA999692979182927864Normal (\>90 to ≤150)1000/50072.8\
(42--139)231\
(161--311)1009896999691968979Mild impairment (\>50 to ≤90)1000/50093.4\
(75.8--141)315\
(255--342)100100991009997999792Moderate impairment (≥29 to ≤50)500/25084.5\
(64--136)589\
(306--900)10010010010010099999794Severe impairment (≥15 to \<29)250/12544.2\
(30.2--60.6)509\
(429--762)1001001001009998969388ESRD with hemodialysis500/250; 100/50^a^41.1\
(17.5--56.4)574\
(287--1024)100100100100100100100100100No PK data were available from patients with ARC in the clinical trials, thus no observed values for *C* ~max~ or AUC are available for those patients*ARC* augmented renal clearance, *AUC* ~*0*--*∞*~ area under the concentration--time curve extrapolated to infinity, *C* ~*max*~ maximum concentration, *CrCl* creatinine clearance, *ESRD* end-stage renal disease, *fT* \> *MIC* free-drug time above MIC, *MIC* minimum inhibitory concentration, *NA* not applicable, *PTA* probability of target attainment, *TOL/TAZ* ceftolozane/tazobactam^a^500/250 mg loading dose followed by 100/50 mg maintenance doses Table 2Summary of the observed *C* ~max~ and AUC~0-∞~ after a single dose and simulated probability of tazobactam target attainment at steady state based on renal functionRenal function category (CrCl, mL/min)TOL/TAZ, mg (1-h infusion)*C* ~max~, µg/mL\
median (range)AUC~0--∞~, µg h/mL\
median (range)PTA ≥20% *f*T \> MEC^b^\
MEC = 1 mg/mLARC (\>150 to ≤200)1000/500NANA91Normal (\>90 to ≤150)1000/50017.0 (14.7--31.4)30.1 (21.7--40.4)97Mild impairment (\>50 to ≤90)1000/50021.9 (18.9--28.3)34.7 (29.1--43.4)100Moderate impairment (≥29 to ≤50)500/25027.1 (23.3--28.7)65.9 (49.1--91.9)100Severe impairment (≥15 to \<29)250/12516.3 (10.2--18.3)56.5 (35.8--70.9)99ESRD with hemodialysis500/250; 100/50^a^14.9 (7.2--22.9)^b^40.3 (23.3--58.6)^b^94^c^No PK data were available from patients with ARC in the clinical trials, thus, no observed values for *C* ~max~ or AUC are available for those patients*ARC* augmented renal clearance, *AUC* ~*0*--*∞*~ area under the concentration--time curve extrapolated to infinity, *C* ~*max*~ maximum concentration, *CrCl* creatinine clearance, *ESRD* end-stage renal disease, *fT* \> *MEC* free-drug time above MEC, *MEC* minimum effective concentration, *NA* not applicable, *PTA* probability of target attainment, *TOL/TAZ* ceftolozane/tazobactam^a^500/250 mg loading dose followed by 100/50 mg maintenance doses^b^Measurements taken on hemodialysis and with 500/250 mg dose^c^Steady state for non-ESRD patients and lowest value on the day immediately after hemodialysis for ESRD/hemodialysis patients

The most recent surveillance data for ceftolozane/tazobactam (2015) demonstrated that MIC~50/90~ values for isolates from the United States and the European Union, respectively, were 0.5/1 and 0.5/16 mg/L for *P. aeruginosa* and 0.25/1 and 0.25/2 mg/L for Enterobacteriaceae \[[@CR19]; data on file\]. Monte Carlo simulation results showed that the percentage of simulated patients achieving %*f*T \> MIC targets increased as the MIC value or the magnitude of the target decreased. Up to an MIC of 8 mg/L, ≥93% of patients across all renal function impairment categories (mild, moderate, severe, ESRD) achieved the target for bactericidal activity (i.e., 32.2% *f*T \> MIC) (Table [1](#Tab1){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}a, b).Fig. 2Simulated ceftolozane PK/PD target attainment \[32.2% *f*T \> MIC target (1-log kill)\] at steady state by renal function group across MIC values following administration of the approved dose regimens. Histograms show MIC distributions for 2015 surveillance isolates \[[@CR19]; data on file\]. **a** *P. aeruginosa* \[MIC~90~, 1 mg/L (United States), 16 mg/L (European Union)\]. **b** Enterobacteriaceae \[MIC~90~, 1 mg/L (United States), 2 mg/L (European Union)\]. *CrCl* creatinine clearance, *ESRD* end-stage renal disease, *HD* hemodialysis, *MIC* minimum inhibitory concentration, *PD* pharmacodynamics, *PK* pharmacokinetics

In the ARC category at the 1.5-g ceftolozane/tazobactam dose, ≥91% of patients achieved 32.2% *f*T \> MIC up to 4 mg/L. Among patients with normal and mild renal impairment, the 32.2% *f*T \> MIC target was achieved with 1.5 g ceftolozane/tazobactam in ≥96% of patients at MICs up to 4 mg/L. At the corresponding adjusted doses, ≥99% of patients with moderate to severe renal impairment achieved the 32.2% *f*T \> MIC targets at MICs up to 4 mg/L. In patients with ESRD, a regimen of 750-mg ceftolozane/tazobactam loading dose followed by 150-mg maintenance dose resulted in 100% target attainment for up to 40% *f*T \> MIC targets at MICs up to 4 mg/L on all days (Table [1](#Tab1){ref-type="table"}).

PK/PD Target Attainment for Tazobactam {#Sec9}
--------------------------------------

In patients with normal renal function at the 1.5-g ceftolozane/tazobactam dose, the estimated probability of target attainment for tazobactam at the 20% *f*T \> MEC target was 97% for an MEC of 1 mg/L. Among patients with ARC, ≥91% achieved tazobactam 20% *f*T \> MEC target attainment (Table [2](#Tab2){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Simulated tazobactam PK/PD target attainment (20% *f*T \> MEC) at steady state by renal function group across MEC values following administration of the approved dose regimens. *CrCl* creatinine clearance, *ESRD* end-stage renal disease, *fT* \> *MEC* free-drug time above MEC, *HD* hemodialysis, *MEC* minimum effective concentration, *PD* pharmacodynamics, *PK* pharmacokinetics

For the mild, moderate, and severe categories of renal impairment, ≥99% of patients achieved the 20% *f*T \> MEC target at the recommended ceftolozane/tazobactam dosing regimen.

For ESRD, the predicted target attainment for tazobactam at the 20% *f*T \> MEC target was ≥94% on all days of the recommended dosing regimen.

Discussion {#Sec10}
==========

Because ceftolozane/tazobactam is renally excreted, renal function is a significant factor influencing PK, with drug clearance decreasing substantially with increasing renal impairment \[[@CR7]\]. Appropriate creatinine measurements that can accurately reflect renal function are critical for dose adjustment, especially at the initial doses. If the baseline creatinine measurement is low, dose adjustment may lead to suboptimal exposure and poor treatment outcome. Therefore, supporting clinical markers to confirm actual renal impairment (compared with normal renal function) should be considered before a patient receives a reduced dose.

As is the case with other cephalosporins, the efficacy of ceftolozane/tazobactam is best correlated with %*f*T \> MIC \[[@CR11]\]. Using Monte Carlo simulations, we showed that the probability of target attainment in the most conservative case is estimated to be ≥91% for 1-log kill and ≥82% for 2-log kill bactericidal activity in patients with ARC or mild, moderate, or severe renal impairment, and in ESRD patients at the recommended dosing regimens at MICs up to 2 and 4 mg/L, corresponding to the current Enterobacteriaceae and *P. aeruginosa* breakpoints, respectively. Monte Carlo simulation of tazobactam showed that ≥91% of patients achieved the target of 20% *f*T \> MEC of 1 mg/L for all renal function categories. Although PK/PD target attainment for tazobactam was not used for dose optimization for the other categories of renal impairment, it was the driver for dose optimization in ESRD patients because the elimination pathway through metabolism (20% in healthy volunteers with normal renal function) \[[@CR4], [@CR5]\] became more important than renal clearance in this group of patients.

In general, the achieved high target attainment for the primary targets for both ceftolozane (≥32.2% *f*T \> MIC) and tazobactam (≥20% *f*T \> MEC of 1 mg/L) at the approved doses was consistent with the high clinical success rate from the phase 3 ASPECT-cUTI and -cIAI trials \[[@CR20], [@CR21]\], suggesting the validity of the targets.

This study had various limitations. First, although MICs of ceftolozane/tazobactam were determined in the presence of 4 mg/L tazobactam, as recommended by the CLSI \[[@CR22]\], PTA estimates for ceftolozane were based solely on ceftolozane, an approach that has validity for non-ESBL-producing pathogens in patients. For ESBL-producing pathogens, published data support tazobactam as an inhibitor of β-lactamase activity and indicate that the PD driver for tazobactam is the percentage of time above a threshold concentration (%*f*T \> threshold) \[[@CR23]\]. Given that our data suggest that the highest tazobactam threshold was 1 mg/L against ESBL-producing pathogens, under the condition of high attainment for this target, PTA calculations using ceftolozane alone appear to be a practical and reasonable approach. PTA calculations based on the combination of ceftolozane and tazobactam are mechanistically interesting, but the methodology on the optimal way to model two components (a cephalosporin and a β-lactamase inhibitor) simultaneously is still under discussion, and several potential approaches have been proposed \[[@CR24]--[@CR27]\]. Nevertheless, the individual exposure of ceftolozane (%*f*T \> MIC) and tazobactam (%*f*T \> MEC) in patients with normal function is high at the 1.5-g dose and was confirmed to be efficacious in clinical trials for cUTIs and cIAIs against both non-ESBL-producing and ESBL-producing pathogens \[[@CR20], [@CR21]\]. Second, this study was limited by the lack of clinical data to support the findings in ARC, severe renal impairment, and ESRD. Recent case studies, however, have reported successful clinical outcomes in patients with more severe renal impairment \[[@CR28], [@CR29]\]. Third, this study was based on population PK models and simulations with characteristics from patients not critically ill, though still infected, or from patients with ESRD who were otherwise healthy. In contrast, many critically ill patients have lower drug clearances, larger volumes of distribution, and, consequently, longer terminal half-lives than healthy persons. These factors are to be confirmed by the ongoing study in critically ill patients (ClinicalTrials.gov, NCT02387372). Finally, this study does not include the case for patients with ARC higher than 200 mL/min or the case for tissue infection in which penetration of the drug into the infected tissue site might be low (for example, penetration into lung tissue in patients with pneumonia). In both cases, a higher dose might be necessary. Indeed, a higher dose of 3 g ceftolozane/tazobactam has been well tolerated in PK studies \[[@CR10], [@CR30]\] and is being evaluated in a phase 3 trial in patients with ventilated nosocomial pneumonia (ClinicalTrials.gov, NCT02070757).

Conclusions {#Sec11}
===========

This analysis confirms that the approved dosing regimens for ceftolozane/tazobactam in patients with mild, moderate, or severe renal impairment and in patients with ESRD are sufficient to achieve high target attainment for bactericidal activity at all the approved breakpoints.
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